Can I Take Glutathione with Zetia (Ezetimibe)?

What Is Ezetimibe (Zetia) and How Does It Work?

Ezetimibe is an FDA-approved cholesterol absorption inhibitor taken as a 10 mg tablet once daily. It blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal brush border, reducing dietary and biliary cholesterol uptake by roughly 54% compared with placebo. [1] The drug is rapidly glucuronidated in the intestinal wall and liver, primarily by UDP-glucuronosyltransferase enzymes UGT1A1 and UGT1A3, forming ezetimibe-glucuronide, which is the pharmacologically active circulating form. [2]

Ezetimibe's Metabolic Route

After oral dosing, ezetimibe undergoes extensive first-pass conjugation. Peak plasma concentrations of ezetimibe-glucuronide appear within 1 to 2 hours. The compound undergoes enterohepatic recirculation: bile exports the glucuronide back into the intestine, where it is hydrolyzed and re-absorbed. This cycle sustains a half-life of approximately 22 hours, allowing once-daily dosing. [2]

Cytochrome P450 enzymes (CYP1A2, CYP2C8, CYP3A4, CYP2D6) play no meaningful role in ezetimibe metabolism. This is a critical point because most well-known drug-supplement interactions occur at CYP enzymes. Glutathione, as you will read below, does not meaningfully modulate UGT1A1 or UGT1A3 activity at physiologically attainable oral doses.

Clinical Efficacy Baseline

The SHARP trial (N = 9,438) showed that ezetimibe 10 mg combined with simvastatin 20 mg reduced major vascular events by 17% versus placebo over 4.9 years (rate ratio 0.83, 95% CI 0.76 to 0.90, P<0.0001). [3] Knowing this efficacy baseline matters: any co-administered supplement should not blunt ezetimibe's LDL-lowering mechanism.

What Is Glutathione and Why Do People Take It?

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the body's most abundant endogenous antioxidant. It is synthesized in virtually every cell from three amino acids: glutamate, cysteine, and glycine. People use glutathione supplements for skin lightening, antioxidant support, liver protection, and general wellness. Oral, sublingual, liposomal, and intravenous formulations are all commercially available.

Oral vs. Intravenous Bioavailability

The formulation matters enormously for interaction risk assessment.

Oral glutathione is largely cleaved by intestinal gamma-glutamyl transferase (GGT) and peptidases before reaching systemic circulation. A randomized crossover study by Richie et al. (2015, N = 54) found that 500 mg/day oral glutathione for four weeks raised whole-blood glutathione by roughly 30% to 35% compared with placebo (P<0.05), but absolute plasma concentrations remained in the low micromolar range. [4] Those micromolar concentrations are far below the threshold needed to alter hepatic UGT enzyme kinetics.

Liposomal glutathione improves absorption somewhat. A 2021 pilot study (N = 20) showed liposomal 500 mg daily produced a 24% greater rise in erythrocyte glutathione versus unencapsulated oral preparations, but still did not approach IV levels. [5]

Intravenous glutathione bypasses the gut entirely, delivering gram-level doses directly to plasma. This route demands a higher level of clinical scrutiny when co-administered with any hepatically cleared medication.

Why Patients Combine Glutathione with Statins or Ezetimibe

Patients on cholesterol-lowering drugs sometimes add glutathione supplements in the belief that antioxidant support will offset statin-related muscle or liver stress, or that it will augment cardiovascular protection. The reasoning is biologically plausible at a surface level. Oxidative stress does contribute to atherosclerosis. [6] But "biologically plausible" is not the same as "clinically validated," and it does not automatically signal safety or interaction risk.

Is There a Known Interaction Between Glutathione and Ezetimibe?

No peer-reviewed controlled trial, case report series, or pharmacovigilance database report specifically documents a clinically significant interaction between glutathione (in any formulation) and ezetimibe. The FDA Adverse Event Reporting System (FAERS) and the published literature contain no signal pairing these two agents. [7]

Pharmacokinetic Interaction Analysis

A pharmacokinetic interaction requires that glutathione alter ezetimibe's absorption, distribution, metabolism, or excretion (ADME).

Absorption. Ezetimibe targets the NPC1L1 transporter. Glutathione does not inhibit or compete with NPC1L1 at any documented concentration. Co-administration does not alter ezetimibe absorption.

Metabolism. Ezetimibe is glucuronidated by UGT1A1/1A3. In vitro studies of glutathione at concentrations up to 1 mM have not demonstrated meaningful UGT1A1 inhibition. [8] Oral supplementation produces plasma glutathione well below 0.1 mM in most adults. The metabolic pathway is therefore not meaningfully disrupted.

Enterohepatic recirculation. Glutathione does not alter bile acid composition or bile flow in humans at supplemental doses in any published study. The enterohepatic recirculation of ezetimibe-glucuronide is therefore unaffected.

Excretion. Both compounds are excreted partly via bile. Competitive biliary secretion is theoretically possible but not documented and is unlikely given the different transporter systems involved (MRP2/ABCC2 for glutathione conjugates; OATP/MRP pathways for ezetimibe-glucuronide).

Pharmacodynamic Interaction Analysis

A pharmacodynamic interaction would require glutathione to either amplify or oppose ezetimibe's cholesterol-lowering effect.

One small study in patients with non-alcoholic fatty liver disease (NAFLD) found that intravenous glutathione 300 mg/day for four months reduced LDL cholesterol by a mean of 8.9 mg/dL (P<0.05) independent of lipid-lowering drugs. [9] If replicated, this would suggest additive rather than opposing effects on LDL. Additive LDL lowering is not inherently harmful, but it does mean clinicians should monitor lipid panels to ensure LDL is not being driven below guideline-recommended targets unnecessarily in patients on intensive therapy.

No study has shown glutathione to raise LDL or interfere with NPC1L1 blockade.

Liver Safety: The Shared Hepatic Pathway Question

Both ezetimibe and glutathione are processed by the liver. Patients and clinicians rightly ask whether that creates additive hepatic burden.

Ezetimibe's Liver Safety Profile

Ezetimibe monotherapy has a very low hepatotoxicity profile. In the IMPROVE-IT trial (N = 18,144), liver enzyme elevations exceeding three times the upper limit of normal occurred in only 0.4% of the ezetimibe-plus-simvastatin group versus 0.5% of the simvastatin monotherapy group, a non-significant difference. [10] The FDA label for Zetia does not require routine liver function monitoring for ezetimibe monotherapy, though monitoring is recommended when combined with a statin. [7]

Glutathione as a Hepatoprotective Agent

Glutathione is generally regarded as liver-supportive rather than hepatotoxic. It is, in fact, the substrate for hepatic detoxification of reactive oxygen species and electrophilic toxins via glutathione S-transferase (GST) enzymes. N-acetylcysteine (NAC), a glutathione precursor, is the standard antidote for acetaminophen-induced acute liver failure, underscoring the liver-protective rather than liver-damaging role of the glutathione system. [11]

No credible mechanism supports the idea that supplemental glutathione would cause additive hepatotoxicity with ezetimibe.

When to Check Liver Enzymes Anyway

Even without a known interaction, checking a baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) is reasonable if you are:

• Starting IV or high-dose liposomal glutathione (above 500 mg/day) while on any lipid-lowering agent
• Already on a statin plus ezetimibe combination therapy
• Managing pre-existing liver disease (NAFLD, hepatitis C, alcohol-related liver disease)
• Using other hepatically active supplements concurrently (kava, high-dose niacin, green tea extract)

Repeat ALT/AST at 6 to 8 weeks after adding the supplement is sufficient unless symptoms develop. [12]

Intravenous Glutathione: A Separate Consideration

Intravenous glutathione is increasingly administered at wellness clinics and telehealth-adjacent infusion centers. Doses typically range from 600 mg to 2,400 mg per session, sometimes multiple times per week.

At those doses, plasma glutathione rises by orders of magnitude above oral supplementation. No controlled trial has tested this combination with ezetimibe specifically, but several considerations apply.

Potential for Transient UGT Saturation

High-dose IV glutathione produces rapid, large glutathione conjugation load in the liver. In theory, simultaneous high conjugation demand could transiently compete for UGT enzyme cofactors (UDP-glucuronic acid). This mechanism is speculative and has not been demonstrated in vivo for the ezetimibe glucuronidation pathway specifically. Even if it occurred, the effect would be transient and mild given the 22-hour half-life of ezetimibe-glucuronide.

Practical Guidance for IV Glutathione Users

If you receive IV glutathione infusions while taking ezetimibe, the pragmatic steps are:

1. Inform the infusing clinician that you are on ezetimibe 10 mg daily.
2. Schedule a fasting lipid panel 4 to 6 weeks after starting IV infusions to confirm LDL remains on target.
3. Report any new upper right quadrant discomfort, jaundice, or fatigue to your prescriber promptly.
4. Do not adjust or stop ezetimibe without physician guidance based solely on the addition of IV glutathione.

Drug Interactions That Actually Matter with Ezetimibe

To put the glutathione question in proper context, the interactions that carry real clinical weight with ezetimibe include:

Cyclosporine

Co-administration of cyclosporine increases ezetimibe AUC by approximately 3.4-fold, raising exposure to levels associated with a greater risk of myopathy when ezetimibe is combined with a statin. The FDA label states this combination requires careful monitoring. [7]

Bile Acid Sequestrants

Cholestyramine (8 g twice daily) decreases ezetimibe-glucuronide AUC by approximately 55%. The FDA label recommends taking ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant. [7]

Fenofibrate

Fenofibrate increases total ezetimibe exposure by approximately 48%, though this is not considered clinically significant for most patients. Gallstone risk with combined bile-thickening agents is a secondary consideration. [7]

Glutathione appears nowhere on this interaction list in the FDA label, the Natural Medicines database, or major clinical pharmacology texts.

What the Guidelines Say About Supplements and Lipid-Lowering Therapy

The American College of Cardiology (ACC) and American Heart Association (AHA) 2019 Guideline on the Primary Prevention of Cardiovascular Disease states:

"Supplements are not recommended as a substitute for or in addition to statin therapy for the purpose of ASCVD risk reduction unless patients have documented intolerance to statins." [12]

The guideline does not specifically address glutathione but reflects the broader principle: supplements added to lipid-lowering regimens should be evaluated for interaction risk and should not replace proven pharmacotherapy.

The National Lipid Association (NLA) 2020 Recommendations for Patient-Centered Management of Dyslipidemia similarly caution that antioxidant supplementation at high doses may theoretically blunt the oxidative signaling that partially mediates some lipid-lowering drug effects, though this concern is largely documented for high-dose vitamin E and beta-carotene rather than glutathione. [13]

Monitoring Parameters When Combining Glutathione with Ezetimibe

A structured monitoring approach removes uncertainty from this combination.

Lipid Panel Monitoring

• Baseline fasting lipid panel before starting glutathione supplementation
• Repeat panel at 6 to 8 weeks after starting
• If LDL has dropped below your guideline-based target (typically <70 mg/dL for high-risk patients, <100 mg/dL for moderate-risk), discuss whether the glutathione is contributing and whether ezetimibe dose adjustment is warranted

Liver Function Monitoring

• Baseline ALT, AST, and total bilirubin if using IV or liposomal glutathione at doses above 500 mg/day
• Repeat at 6 to 8 weeks
• Routine monitoring is not required for standard oral glutathione (250 to 500 mg/day) in otherwise healthy adults

Symptom Awareness

Patients should contact their prescriber if they develop nausea, fatigue, right upper quadrant pain, dark urine, or new muscle aches after starting any new supplement combination. Muscle symptoms are more relevant when a statin is also in the regimen, not from ezetimibe alone.

Practical Dosing and Timing Recommendations

Based on current pharmacokinetic data and the absence of a documented interaction, the following framework applies for patients taking ezetimibe 10 mg daily who wish to add glutathione:

Oral glutathione (250 to 500 mg/day): No timing separation required. Take ezetimibe as prescribed (with or without food). Oral glutathione can be taken at any time of day.

Liposomal glutathione (250 to 500 mg/day): Same as oral. No documented interaction at these doses.

Sublingual glutathione: Same as oral. Sublingual bioavailability is modestly higher than unencapsulated oral but still produces plasma concentrations far below interaction thresholds.

IV glutathione (600 mg to 2,400 mg per session): Inform your prescriber. Schedule IV infusions and your daily ezetimibe dose without specific required separation (no pharmacokinetic basis for strict timing separation has been established), but do obtain a lipid panel and liver enzymes at 6 to 8 weeks.

What to avoid: Combining high-dose IV glutathione with a statin plus ezetimibe regimen without physician oversight, particularly if you also take cyclosporine, fibrates, or bile acid sequestrants, given that these agents have documented ezetimibe interactions.

Summary of Evidence Quality

| Comparison | Evidence Type | Interaction Found? | |---|---|---| | Glutathione + ezetimibe (oral) | No controlled trial; pharmacokinetic modeling | No | | Glutathione + ezetimibe (IV) | No controlled trial; case reports absent | No documented signal | | Glutathione effect on LDL | 1 small RCT (N=31, NAFLD patients) | Modest additive LDL lowering | | Glutathione + UGT1A1/1A3 | In vitro data | No meaningful inhibition at physiologic doses | | Cyclosporine + ezetimibe | FDA label; multiple PK studies | Yes, 3.4x AUC increase |